This article is more than 5 years old. Information may no longer be current.

ProQR posts year-end financial results

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

ProQR Therapeutics reported a net loss of 13 million euros, or 0.33 euros per diluted share, in the fourth quarter of 2018 compared with a net loss of 11.3 million euros, or 0.39 euros per diluted share, in 2017’s final quarter, according to a press release.

For the full year, net loss totaled 37.1 million euros, or 1.09 euros per diluted share, compared with a net loss of 43.7 million euros, or 1.72 euros per diluted share, for 2017.

Research and development costs increased from 8.3 million euros to 9.5 million euros for the quarter and decreased from 31.1 million euros to 29.5 million euros for the full year.

General and administrative expenses rose from 2.9 million euros to 4.6 million euros for the quarter and from 10.8 million euros to 12.5 million euros for the year.

ProQR had cash and cash equivalents of 105.6 million euros as of Dec. 31, 2018.